Adoptive cell transfer: A clinical path to effective cancer immunotherapy

Steven A. Rosenberg, Nicholas P. Restifo, James C. Yang, Richard A. Morgan, Mark E. Dudley

Research output: Contribution to journalReview articlepeer-review

1103 Scopus citations


Adoptive cell therapy (ACT) using autologous tumour-infiltrating lymphocytes has emerged as the most effective treatment for patients with metastatic melanoma and can mediate objective cancer regression in approximately 50% of patients. The use of donor lymphocytes for ACT is an effective treatment for immunosuppressed patients who develop post-transplant lymphomas. The ability to genetically engineer human lymphocytes and use them to mediate cancer regression in patients, which has recently been demonstrated, has opened possibilities for the extension of ACT immunotherapy to patients with a wide variety of cancer types and is a promising new approach to cancer treatment.

Original languageEnglish (US)
Pages (from-to)299-308
Number of pages10
JournalNature Reviews Cancer
Issue number4
StatePublished - Apr 2008
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Adoptive cell transfer: A clinical path to effective cancer immunotherapy'. Together they form a unique fingerprint.

Cite this